Epizyme, Inc.
USPTO PatentsView assignee record - 150 granted patents across 16 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Epizyme ranks #2,589 of 49,997 tracked US assignees by granted-patent volume, with 150 patents across 16 technology areas.
- #2,589
- of 49,997 US assignees by volume
- Top 19%
- by Innovation Score (47.3/100)
- 19.0
- avg claims per patent
- -55%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R2589 · US Corporation #2,589 · 150 grants
GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MID 150 grants
- TOP-DECILE #2,589/49,997
- PHOTO-FINISH Auckland Uniservices
- CPC-FOCUS A61P · 16 areas
- INNOV-PAR 47.3/100
- CLAIMS-RICH 19.0 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -55% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Auckland Uniservices Limited (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Epizyme’s 47.3 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Epizyme
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Accton Technology · near
Accton Technology · near
47 score
- Epizyme · this assignee
Epizyme · this assignee
47 score
- Noble Systems · near
Noble Systems · near
47 score
- Nokia Shanghai Bell · near
Nokia Shanghai Bell · near
47 score
- Stradvision · near
Stradvision · near
47 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Epizyme's Innovation Score is 47.3/100 (top 19% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Epizyme?
Each dot is one of Epizyme’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Epizyme’s own 19.0 claims/patent is ABOVE the 14.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Epizyme's grants concentrate
Epizyme, Inc. is a focused PatentsView assignee: 16 CPC subclasses with 88.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (26 grants) versus a trough of 4 in 2022. By volume, Epizyme sits between Auckland Uniservices Limited and Nextracker LLC.
Epizyme's three-year grant acceleration
From 2019–2021 to 2022–2024, Epizyme, Inc. moved from 38 to 25 grants (0.66x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,283. See the growth leaderboard.
Who files at Epizyme's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Auckland Uniservi…
Auckland Uniservices Limited
150 patents
- Canon Production…
Canon Production Printing Holding B.V.
150 patents
- Crowdstrike
CrowdStrike, Inc.
150 patents
- Eberspächer Exhau…
Eberspächer Exhaust Technology GmbH
150 patents
- Goodrich Lighting…
Goodrich Lighting Systems, Inc.
150 patents
- Harmonic Drive Sy…
Harmonic Drive Systems Inc.
150 patents
- Kyoraku
Kyoraku Co., Ltd.
150 patents
- Nextracker
Nextracker LLC
150 patents
- Epizyme ◀
Epizyme, Inc.
150 patents
What this shows Epizyme holds 150 patents at rank #2,589, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Epizyme
By rank, the assignees closest to #2,589 in granted patent volume.
- Auckland Uniservices Limited #2,585 · 150 patents
- Canon Production Printing Holding B.V. #2,586 · 150 patents
- CrowdStrike, Inc. #2,587 · 150 patents
- Eberspächer Exhaust Technology GmbH #2,588 · 150 patents
- Goodrich Lighting Systems, Inc. #2,590 · 150 patents
- Harmonic Drive Systems Inc. #2,591 · 150 patents
- Kyoraku Co., Ltd. #2,592 · 150 patents
- Nextracker LLC #2,593 · 150 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Epizyme's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Epizyme, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Epizyme ranks #109 of 6,058 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (47 here).
Similar claim depth
Nearest assignees by average claims per patent (19.0 here).
Epizyme's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
47 Top 19% higher than 81% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 19 | 12.7% |
| 2016 | 19 | 12.7% |
| 2017 | 26 | 17.3% |
| 2018 | 22 | 14.7% |
| 2019 | 17 | 11.3% |
| 2020 | 11 | 7.3% |
| 2021 | 10 | 6.7% |
| 2022 | 4 | 2.7% |
| 2023 | 12 | 8.0% |
| 2024 | 9 | 6.0% |
| 2025partial year | 1 | 0.7% |
Which technologies does Epizyme, Inc. patent most?
Top 15 of 16 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Epizyme, Inc.'s patent record in context - here's where to go next.
- Epizyme, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 88.7% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #2,589 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Epizyme, Inc. against Auckland Uniservices Limited, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 47.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.